Evidence map›Paper›PMID 22870271›Full record

Trial reportPloS one2012

CD47(low) status on CD4 effectors is necessary for the contraction/resolution of the immune response in humans and mice.

Vu Quang Van, Nobuyasu Baba, Manuel Rubio, Keiko Wakahara, Benoit Panzini, Carole Richard, Genevieve Soucy, Denis Franchimont, Genevieve Fortin, Ana Carolina Martinez Torres and 3 more

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 26 citations in OpenAlex.

  1. CD47 and FOXP3Cancers · 2026
    Review
  2. Review
  3. Emerging functions of thrombospondin-1 in immunity.Seminars in cell & developmental biology · 2024
    Review
  4. CD47/SIRPα axis: bridging innate and adaptive immunity.Journal for immunotherapy of cancer · 2022
    Review
  5. Article
  6. Article
  7. CD47 (Cluster of Differentiation 47).Atlas of genetics and cytogenetics in oncology and haematology · 2021
    Article
  8. Article
  9. Article
  10. Article
  11. Regulatory T cell memory.Nature reviews. Immunology · 2016
    Review
  12. Article
  13. Article
  14. CD4 T-cell memory generation and maintenance.Critical reviews in immunology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 3 countries.

Vu Quang VanImmunoregulation Laboratory, Centre Hospitalier de l'Université de Montréal, Research Center (CRCHUM), Notre-Dame Hospital, Montreal, Quebec, Canada.
Nobuyasu Baba
Manuel Rubio
Keiko Wakahara
Benoit Panzini
Carole Richard
Genevieve Soucy
Denis Franchimont
Genevieve Fortin
Ana Carolina Martinez Torres
Lauriane Cabon
Santos Susin
Marika Sarfati
Centre Hospitalier de l’Université de Montréal · CAHôpital Notre-Dame · CADélégation Paris 5 · FRInserm · FRMcGill University Health Centre · CASorbonne Université · FRUniversité Libre de Bruxelles · BE

Funding

Canadian Institutes of Health Research MOP-102562
6 · The paper itself

Abstract

How do effector CD4 T cells escape cell death during the contraction of the immune response (IR) remain largely unknown. CD47, through interactions with thrombospondin-1 (TSP-1) and SIRP-α, is implicated in cell death and phagocytosis of malignant cells. Here, we reported a reduction in SIRP-α-Fc binding to effector memory T cells (T(EM)) and in vitro TCR-activated human CD4 T cells that was linked to TSP-1/CD47-induced cell death. The reduced SIRP-α-Fc binding (CD47(low) status) was not detected when CD4 T cells were stained with two anti-CD47 mAbs, which recognize distinct epitopes. In contrast, increased SIRP-α-Fc binding (CD47(high) status) marked central memory T cells (T(CM)) as well as activated CD4 T cells exposed to IL-2, and correlated with resistance to TSP-1/CD47-mediated killing. Auto-aggressive CD4 effectors, which accumulated in lymph nodes and at mucosal sites of patients with Crohn's disease, displayed a CD47(high) status despite a high level of TSP-1 release in colonic tissues. In mice, CD47 (CD47(low) status) was required on antigen (Ag)-specific CD4 effectors for the contraction of the IR in vivo, as significantly lower numbers of Ag-specific CD47(+/+)CD4 T cells were recovered when compared to Ag-specific CD47(-/-) CD4 T cells. In conclusion, we demonstrate that a transient change in the status of CD47, i.e. from CD47(high) to CD47(low), on CD4 effectors regulates the decision-making process that leads to CD47-mediated cell death and contraction of the IR while maintenance of a CD47(high) status on tissue-destructive CD4 effectors prevents the resolution of the inflammatory response.

Indexed as

Clonal DeletionImmunologic MemoryAnimalsAntigens, DifferentiationCD47 AntigenCD4-Positive T-LymphocytesCell DeathCrohn DiseaseFemaleHumansInterleukin-2MaleMiceMice, KnockoutReceptors, ImmunologicAntigens, DifferentiationCD47 AntigenCD47 protein, humanCd47 protein, mouseIL2 protein, humanInterleukin-2Receptors, ImmunologicSIRPA protein, humanSirpa protein, mouse

Identifiers

PMID22870271
PMCPMC3411572
OpenAlexW2035126650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.